Cytokinetics Insider Sold Shares Worth $615,150, According to a Recent SEC Filing

Robert I Blum, Director, President & CEO, on July 13, 2026, sold 7,500 shares in Cytokinetics (CYTK) for $615,150. Following the Form 4 filing with the SEC, Blum has control over a total of 381,986 common shares of the company, with 377,820 shares held directly and 4,166 controlled indirectly. SEC Filing: Price: $81.68, Change: $-0.56, Percent Change: -0.68%